In an adolescent or young adult with neurofibromatosis type 1 who presents with a rapidly enlarging, painful peripheral nerve mass, what is the recommended diagnostic work‑up and first‑line management for malignant peripheral nerve sheath tumor (MPNST)?

Management of Malignant Peripheral Nerve Sheath Tumor (MPNST) in NF1 Patients

In an adolescent or young adult with NF1 presenting with a rapidly enlarging, painful peripheral nerve mass, proceed immediately with FDG-PET or diffusion-weighted MRI followed by image-guided core needle biopsy (minimum 6 cores with 14-18G needles) and comprehensive molecular profiling, then pursue complete surgical resection with wide negative margins as the definitive treatment, with adjuvant radiation therapy ≥60 Gy for local control. 1, 2

Diagnostic Work-Up Algorithm

Initial Imaging Assessment

• Obtain FDG-PET or diffusion-weighted MRI for any rapidly growing, painful, or radiologically concerning peripheral nerve mass in NF1 patients 1, 3
• Use SUVmax threshold of 3.5 on FDG-PET as the cutoff for proceeding to biopsy 1
• Look for decreased apparent diffusion coefficient (ADC) on diffusion-weighted MRI, which suggests malignant transformation 3

Tissue Acquisition Strategy

Core needle biopsy is the recommended approach rather than excisional biopsy to avoid compromising subsequent surgical margins 1, 4

• Use 14-18G core biopsy needles with image guidance 1, 3
• Obtain minimum of 6 core biopsies if safe and feasible to account for intratumoral heterogeneity, which is a critical pitfall in MPNST diagnosis 1, 3
• Target multiple radiologically-concerning areas identified on PET or MRI, labeling each biopsy site container separately 3
• Divide cores into multiple blocks with no more than 2 cores per block to preserve tissue for molecular testing 4

Histopathologic Evaluation

The pathologist must assess the following specific features 1, 4:

• Cytologic atypia
• Loss of neurofibromatous architecture
• Hypercellularity
• Mitotic count per 10 high-power fields (HPF)
• Presence of necrosis (defining feature of high-grade MPNST)

High-grade MPNST criteria: Brisk mitotic activity plus tissue necrosis 2

Immunohistochemistry Panel

Required stains include 3, 4:

• Reduced SOX10 and/or S100 expression
• Loss of CD34-positive lattice-like network
• Complete loss of p16 expression (suggests CDKN2A/B deletion)
• Complete H3K27me3 loss (indicates SUZ12 or EED inactivation)
• Increased p53 immunoreactivity (suggests TP53 mutation)

Molecular Profiling (Critical Step)

All clinically or radiologically worrisome noncutaneous lesions in NF1 patients require molecular profiling 2, 1

The 2025 Neuro-Oncology consensus guidelines emphasize this integrated diagnostic approach as essential for accurate diagnosis and early identification of malignant transformation 2

Key molecular features to assess:

• CDKN2A/B inactivation (defines ANNUBP) 2
• SUZ12 or EED inactivating mutations (diagnostic for MPNST) 2
• TP53 inactivating mutations (diagnostic for MPNST) 2
• Significant aneuploidy (diagnostic for MPNST) 2

Use a comprehensive next-generation sequencing panel with copy number and zygosity assessment 3

First-Line Management

Surgical Management (Cornerstone of Treatment)

Complete surgical resection with wide negative margins is the primary and most critical treatment for all localized MPNSTs 1, 5

• This is the only known curative therapy 5
• Resection should include the tumor with negative margins and typically requires sacrifice of the nerve of origin 1
• Aggressive oncologic surgical approach is mandatory even for large, non-extremity tumors 1
• Incomplete resection is the major cause of treatment failure 6

Adjuvant Radiation Therapy

Postoperative radiation therapy to doses ≥60 Gy is recommended to improve local control, particularly when margins are positive or uncertain 1

• Radiation appears to have a role in improving local control, though this must be balanced against potential morbidity, especially in adolescents 6
• For retroperitoneal MPNSTs specifically, postoperative radiotherapy has limited value and significant toxicities, and should only be considered in selected cases with well-defined areas at risk 1

Role of Chemotherapy

The role of chemotherapy remains uncertain with no randomized studies demonstrating clear benefit 1

However, chemotherapy may be considered in specific scenarios:

• Doxorubicin plus ifosfamide achieves response rates of approximately 21% in advanced/metastatic MPNST 1
• Preoperative chemotherapy can be considered for borderline resectable tumors 1
• Meta-analysis suggests there may be a role for adjuvant chemotherapy in some patients with non-metastatic disease, though evidence is not definitive 1

Critical Pitfalls and Caveats

Intratumoral Heterogeneity

MPNST often arises from preexisting lower-grade precursor lesions, and intratumoral heterogeneity is common 2. This is why:

• Multiple core biopsies from different areas are essential 1, 3
• Single biopsy may miss high-grade areas
• Molecular profiling helps identify malignant transformation even in histologically ambiguous areas 2

Terminology Update

The 2025 consensus guidelines recommend renaming "low-grade MPNST" to "ANNUBP with increased proliferation" to avoid using the term "malignant" in tumors with persistent unknown biologic potential 2

Prognosis Considerations

• High-grade MPNSTs have approximately 20% 5-year survival 1
• NF1-associated MPNSTs have increased mortality compared to sporadic cases 1
• Rapidly enlarging and painful masses in NF1 patients are high-risk features requiring urgent evaluation 3, 7
• The lifetime risk of MPNST in NF1 patients is 8-13% compared to 0.001% in the general population 6, 8

Multidisciplinary Approach

Patients should be evaluated by a specialized multidisciplinary team, ideally at a dedicated neurofibromatosis clinic, as this approach significantly reduces morbidity and mortality 4